{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:34:43Z","timestamp":1789058083052,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The epidemiology of invasive aspergillosis (IA) is evolving. To define the patient groups who will most likely benefit from primary or secondary Aspergillus prophylaxis, particularly those whose medical conditions and IA risk change over time, it is helpful to depict patient populations and their risk periods in a temporal visual model. The Sankey approach provides a dynamic figure to understand the risk of IA for various patient populations. While the figure depicted within this article is static, an internet-based version could provide pop-up highlights of any given flow's origin and destination nodes. A future version could highlight links to publications that support the color-coded incidence rates or other actionable items, such as bundles of applicable pharmacologic or non-pharmacologic interventions. The figure, as part of the upcoming Infectious Diseases Society of America's aspergillosis clinical practice guidelines, can guide decision-making in clinical settings.<\/jats:p>","DOI":"10.1093\/ofid\/ofae082","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T17:52:19Z","timestamp":1707241939000},"source":"Crossref","is-referenced-by-count":18,"title":["Modeling Invasive Aspergillosis Risk for the Application of Prophylaxis Strategies"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4182-341X","authenticated-orcid":false,"given":"Jo-Anne H","family":"Young","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Minnesota , Minneapolis, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-9950","authenticated-orcid":false,"given":"David R","family":"Andes","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Medical Microbiology and Immunology, University of Wisconsin\u2013Madison , Madison, Wisconsin , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2853-2581","authenticated-orcid":false,"given":"Monica I","family":"Ardura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Ohio State University College of Medicine , Columbus, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Arrieta","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children's Hospital of Orange County , Orange, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3879-0549","authenticated-orcid":false,"given":"Eric J","family":"Bow","sequence":"additional","affiliation":[{"name":"Departments of Medical Microbiology and Infectious Diseases, and Internal Medicine, CancerCare Manitoba and the University of Manitoba , Winnipeg , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0774-1058","authenticated-orcid":false,"given":"Pranatharthi H","family":"Chandrasekar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Wayne State University , Detroit, Michigan , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9983-6603","authenticated-orcid":false,"given":"Sharon C A","family":"Chen","sequence":"additional","affiliation":[{"name":"Centre of Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital and the University of Sydney , Sydney, New South Wales , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-7443","authenticated-orcid":false,"given":"Sarah P","family":"Hammond","sequence":"additional","affiliation":[{"name":"Divisions of Infectious Diseases and Hematology Oncology, Massachusetts General Hospital, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9216-5229","authenticated-orcid":false,"given":"Shahid","family":"Husain","sequence":"additional","affiliation":[{"name":"University Health Network, University of Toronto , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Koo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2770-1360","authenticated-orcid":false,"given":"Val\u00e9ry","family":"Lavergne","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Control, Vancouver General Hospital, Vancouver, British Columbia, University of Montreal Research Center , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2065-3239","authenticated-orcid":false,"given":"M Hong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9513-7127","authenticated-orcid":false,"given":"Thomas F","family":"Patterson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Texas Health Science Center at San Antonio , San Antonio, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2765-2063","authenticated-orcid":false,"given":"Miranda","family":"So","sequence":"additional","affiliation":[{"name":"University Health Network, University of Toronto , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-5750","authenticated-orcid":false,"given":"George R","family":"Thompson","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine and Medical Microbiology and Immunology, University of California, Davis , Davis, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9970-9575","authenticated-orcid":false,"given":"C Orla","family":"Morrissey","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Monash University , Melbourne, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0597-7411","authenticated-orcid":false,"given":"Mindy G","family":"Schuster","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"2024032721425988800_ofae082-B1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024032721425988800_ofae082-B2","first-page":"218","article-title":"Exploring patient path through Sankey diagram: a proof of concept","volume":"270","author":"Lamer","year":"2020","journal-title":"Stud Health Technol Inform"},{"key":"2024032721425988800_ofae082-B3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3102\/10769986027001031","article-title":"Visions and re-visions of Charles Joseph Minard","volume":"27","author":"Friendly","year":"2002","journal-title":"J Educ Behav Stat"},{"key":"2024032721425988800_ofae082-B4","first-page":"278","article-title":"The thermal efficiency of steam-engines","volume":"134","author":"Kennedy","year":"1898","journal-title":"Minutes Proc Inst Civ Eng"},{"key":"2024032721425988800_ofae082-B5","author":"Schmidt"},{"key":"2024032721425988800_ofae082-B6","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/516480","article-title":"Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation","volume":"175","author":"Wald","year":"1997","journal-title":"J Infect Dis"},{"key":"2024032721425988800_ofae082-B7","doi-asserted-by":"crossref","first-page":"e14101","DOI":"10.1111\/tid.14101","article-title":"Updates in hematopoietic cell transplant and cellular therapies that enhance the risk for opportunistic infections","volume":"25","author":"Cuvelier","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"2024032721425988800_ofae082-B8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbmt.2015.09.013","article-title":"Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors","volume":"22","author":"Young","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024032721425988800_ofae082-B9","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.bbmt.2016.06.012","article-title":"Infection rates among acute leukemia patients receiving alternative donor hematopoietic cell transplantation","volume":"22","author":"Ballen","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024032721425988800_ofae082-B10","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"2024032721425988800_ofae082-B11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"2024032721425988800_ofae082-B12","doi-asserted-by":"crossref","first-page":"509 e1","DOI":"10.1016\/j.jtct.2022.05.008","article-title":"Steroid-sensitive, but not steroid-dependent or steroid-resistant acute graft-versus-host disease, results in similar infection risk as no graft-versus-host disease following allogeneic hematopoietic cell transplantation","volume":"28","author":"Young","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2024032721425988800_ofae082-B13","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"2024032721425988800_ofae082-B14","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024032721425988800_ofae082-B15","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/bloodadvances.2020003937","article-title":"Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes","volume":"5","author":"El Jurdi","year":"2021","journal-title":"Blood Adv"},{"key":"2024032721425988800_ofae082-B16","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss","year":"2019","journal-title":"Blood Adv"},{"key":"2024032721425988800_ofae082-B17","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1080\/10428194.2022.2047964","article-title":"Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax","volume":"63","author":"Chen","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2024032721425988800_ofae082-B18","doi-asserted-by":"crossref","first-page":"ofac486","DOI":"10.1093\/ofid\/ofac486","article-title":"Incidence of invasive fungal infections in patients with previously untreated acute myeloid leukemia receiving venetoclax and azacitidine","volume":"9","author":"Zhang","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024032721425988800_ofae082-B19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.18051","article-title":"Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent","volume":"197","author":"On","year":"2022","journal-title":"Br J Haematol"},{"key":"2024032721425988800_ofae082-B20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"2024032721425988800_ofae082-B21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024032721425988800_ofae082-B22","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"2024032721425988800_ofae082-B23","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1182\/bloodadvances.2022007474","article-title":"Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma","volume":"6","author":"Little","year":"2022","journal-title":"Blood Adv"},{"key":"2024032721425988800_ofae082-B24","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"2024032721425988800_ofae082-B25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"2024032721425988800_ofae082-B26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ccc.2020.09.001","article-title":"Infectious disease complications in patients with cancer","volume":"37","author":"Seo","year":"2021","journal-title":"Crit Care Clin"},{"key":"2024032721425988800_ofae082-B27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12879-021-05958-3","article-title":"Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response","volume":"21","author":"Neofytos","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2024032721425988800_ofae082-B28","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024032721425988800_ofae082-B29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1086\/430602","article-title":"Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study","volume":"41","author":"Gavalda","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2024032721425988800_ofae082-B30","doi-asserted-by":"crossref","first-page":"ofw171","DOI":"10.1093\/ofid\/ofw171","article-title":"Invasive aspergillosis associated with severe influenza infections","volume":"3","author":"Crum-Cianflone","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2024032721425988800_ofae082-B31","doi-asserted-by":"crossref","first-page":"ofab091","DOI":"10.1093\/ofid\/ofab091","article-title":"Invasive aspergillosis after influenza and other viral respiratory infections among intensive care unit patients in a commercially insured population in the United States, 2013\u20132018","volume":"8","author":"Toda","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024032721425988800_ofae082-B32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3390\/jof9060689","article-title":"Mortality in ICU patients with COVID-19-associated pulmonary aspergillosis","volume":"9","author":"Beltrame","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"2024032721425988800_ofae082-B33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s13054-021-03753-9","article-title":"Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study","volume":"25","author":"Hatzl","year":"2021","journal-title":"Crit Care"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae082\/56591407\/ofae082.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/3\/ofae082\/57090402\/ofae082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/3\/ofae082\/57090402\/ofae082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T21:43:28Z","timestamp":1711575808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae082\/7601784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae082","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,2,6]]},"article-number":"ofae082"}}